ABSTRACT
Results were evaluated for 651 consecutive patients with invasive cancer of the intact uterine cervix. From 1963 through 1967 319 patients were treated primarily with the older Los Angeles County Hospital system of orthovoltage radiation and intracavitary radium therapy. Thereafter, 1968--1974, 332 patients were treated primarily with a newer modified M. D. Anderson Tumor Institute system of megavoltage radiation and afterloading intracavitary radium therapy. Age distribution and histology were similar for both groups, but clinical stage was slightly more advanced for patients treated earlier. Crude and net 5 year survival rates were 36% and 49% for the early group and 54% and 67% for the later group. Net 5 year survival rates for the earlier group by stage were: stage I, 74%; II, 62%; III, 23%; and IV, 6%. Survival rates for the later group were: I, 81%; II 76%; III, 50%; and IV, 15%. We believe this improvement can be attributed to more effective intracavitary radium therapy for handling local cancer and to delivery of cancericidal doses of radiation to regional nodes with the megavoltage radiation apparatus, as well as to the greater cooperative efforts put forth in the management of County Hospital patients.
Subject(s)
Adenocarcinoma/radiotherapy , Carcinoma, Squamous Cell/radiotherapy , Radiotherapy, High-Energy/methods , Radium/administration & dosage , Uterine Cervical Neoplasms/radiotherapy , Adenocarcinoma/mortality , Carcinoma, Squamous Cell/mortality , Female , Humans , Middle Aged , Uterine Cervical Neoplasms/mortalityABSTRACT
Between 1965 and 1973, 80 patients with prostatic carcinoma were treated with definitive supervoltage irradiation; 35 patients received adjuvant estrogens. A favorable tumor response was uniformly observed in patients with less advanced tumors who received a minimum of 6,000 rads tumor dose and adjuvant estrogens. Radiation complications were frequent and severe in patients with locally advanced tumors who had antecedent lower urinary tract surgery and received a minimum of 7,000 rads tumor dose. Complications were less frequent in patients who received adjuvant estrogens, and complications were uncommon and mild in patients who received less than 7,000 rads.
Subject(s)
Adenocarcinoma/therapy , Prostatic Neoplasms/therapy , Radiotherapy/adverse effects , Rectal Diseases/prevention & control , Urologic Diseases/prevention & control , Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Adult , Aged , Cobalt Radioisotopes , Estrogens/therapeutic use , Humans , Male , Middle Aged , Neoplasm Metastasis , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/radiotherapy , Radioisotope Teletherapy , Radiotherapy Dosage , Radiotherapy, High-EnergyABSTRACT
A total of 219 patients with proved lung cancer were studied to determine whether postresection irradiation improves survival. The results showed that postresection irradiation improved survival among patients with hilar and mediastinal lymph-node metastases of all histological types but did not improve survival among patients without node metastases. The authors recommend that patients with resectable lung cancer involving the hilar and mediastinal lymph nodes be treated by a combination of surgery and radiotherapy.
